Whenever possible, we encourage access to our investigational medicine through participation in a clinical trial, which is designed to answer important questions about safety and effectiveness while offering patients the opportunity to contribute to future care.
If a patient cannot join a relevant trial, their treating physician may contact us to discuss other potential pathways for access.
Expanded Access
For patients with serious or life-threatening disease who have exhausted available treatment options and cannot enroll in an appropriate clinical trial, Quercis may consider requests for expanded access to our investigational drug.
These requests must be made by the patient's licensed treating physician and are evaluated case-by-case, taking into account the patient's condition, available scientific evidence, potential risks and benefits, and the need to ensure that expanded access does not compromise ongoing clinical trials or broader development of the medicine.
Where the U.S. Right to Try law applies, we support its goal of providing a possible path to investigational medicines for patients facing serious or life-threatening illness who lack other options.
We believe our existing approach to early access is consistent with these objectives and will carefully review physician requests made under Right to Try, in line with our medical, ethical, and regulatory responsibilities.
